A detailed history of Ubs Group Ag transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 217,619 shares of KYMR stock, worth $8.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
217,619
Previous 210,301 3.48%
Holding current value
$8.31 Million
Previous $6.28 Million 64.08%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.16 - $52.4 $220,710 - $383,463
7,318 Added 3.48%
217,619 $10.3 Million
Q2 2024

Aug 13, 2024

SELL
$29.85 - $39.42 $2.58 Million - $3.41 Million
-86,379 Reduced 29.12%
210,301 $6.28 Million
Q1 2024

May 13, 2024

SELL
$22.9 - $43.57 $86,630 - $164,825
-3,783 Reduced 1.26%
296,680 $11.9 Million
Q4 2023

Feb 09, 2024

BUY
$10.97 - $26.84 $1.51 Million - $3.7 Million
137,704 Added 84.61%
300,463 $7.65 Million
Q3 2023

Nov 09, 2023

SELL
$13.9 - $23.88 $1.08 Million - $1.86 Million
-77,957 Reduced 32.39%
162,759 $2.26 Million
Q2 2023

Aug 11, 2023

BUY
$22.4 - $34.92 $1.24 Million - $1.94 Million
55,421 Added 29.91%
240,716 $5.53 Million
Q1 2023

May 12, 2023

SELL
$24.84 - $38.75 $433,855 - $676,807
-17,466 Reduced 8.61%
185,295 $5.49 Million
Q4 2022

Feb 08, 2023

BUY
$19.57 - $30.92 $3 Million - $4.73 Million
153,076 Added 308.09%
202,761 $5.06 Million
Q3 2022

Nov 10, 2022

SELL
$20.91 - $34.27 $1.29 Million - $2.12 Million
-61,784 Reduced 55.43%
49,685 $1.08 Million
Q2 2022

Aug 10, 2022

SELL
$14.13 - $42.55 $347,894 - $1.05 Million
-24,621 Reduced 18.09%
111,469 $2.19 Million
Q1 2022

May 16, 2022

BUY
$35.3 - $64.68 $2.36 Million - $4.33 Million
66,974 Added 96.9%
136,090 $5.76 Million
Q4 2021

Feb 14, 2022

BUY
$49.91 - $65.56 $2.79 Million - $3.66 Million
55,873 Added 421.91%
69,116 $4.39 Million
Q3 2021

Nov 15, 2021

SELL
$47.8 - $66.66 $635,596 - $886,378
-13,297 Reduced 50.1%
13,243 $778,000
Q2 2021

Aug 13, 2021

BUY
$31.08 - $51.95 $34,125 - $57,041
1,098 Added 4.32%
26,540 $1.29 Million
Q1 2021

May 12, 2021

BUY
$35.64 - $85.46 $777,985 - $1.87 Million
21,829 Added 604.18%
25,442 $989,000
Q4 2020

Feb 11, 2021

BUY
$28.07 - $87.83 $94,932 - $297,041
3,382 Added 1464.07%
3,613 $224,000
Q3 2020

Nov 12, 2020

BUY
$26.1 - $33.28 $6,029 - $7,687
231 New
231 $7,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.09B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.